BR112015030355A8 - use of a protein or an adenylyl cyclase type 6 (ac6) polypeptide incompetent with adenosine cyclic monophosphate (incompetent with camp) or a gene or nucleic acid encoding ac6mut, and, formulation - Google Patents
use of a protein or an adenylyl cyclase type 6 (ac6) polypeptide incompetent with adenosine cyclic monophosphate (incompetent with camp) or a gene or nucleic acid encoding ac6mut, and, formulation Download PDFInfo
- Publication number
- BR112015030355A8 BR112015030355A8 BR112015030355A BR112015030355A BR112015030355A8 BR 112015030355 A8 BR112015030355 A8 BR 112015030355A8 BR 112015030355 A BR112015030355 A BR 112015030355A BR 112015030355 A BR112015030355 A BR 112015030355A BR 112015030355 A8 BR112015030355 A8 BR 112015030355A8
- Authority
- BR
- Brazil
- Prior art keywords
- incompetent
- camp
- ac6mut
- polypeptide
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
1 / 1 resumo âmãtodo para tratar, melhorar, inverter, proteger ou prevenir um indivãduo ou um paciente contra uma patologia, uma cardiopatia ou uma doenãa cardiovascular, uso, e, formulaãão terapãuticaâ a invenã§ã£o proporciona mã©todos para tratar, melhorar ou proteger (prevenir) um indivãduo ou um paciente tendo, ou em risco de ter, uma doenã§a do coraã§ã£o ou insuficiãªncia do coraã§ã£o, ou funã§ã£o cardãaca diminuãda, compreendendo: proporcionar uma proteãna ou polipeptãdeo adenilil ciclase tipo 6 (ac6) incompetente com adenosina monofosfato(incompetente com camp) (tambã©m chamado de "um ac6mut"), ou um gene ou um ã¡cido nucleico que codifica ac6mut operativamente ligado a uma sequãªncia reguladora transcricional.1 / 1 abstract “method to treat, improve, reverse, protect or prevent an individual or a patient against a pathology, a heart disease or a cardiovascular disease, use, and therapeutic formulation The invention provides methods for treating, improving or protecting (preventing) an individual or patient having, or at risk of having, heart disease or heart failure tion, or impaired heart function, comprising: providing an adenosine monophosphate-incompetent (camp-incompetent) adenosine monophosphate (camp-incompetent) adenylyl cyclase (AC6)-incompetent protein or polypeptide (also called "an ac6mut"), or a gene or nucleic acid encoding mc6mut operably linked to a transcriptional regulatory sequence.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832759P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/040948 WO2014197624A1 (en) | 2013-06-07 | 2014-06-04 | Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015030355A2 BR112015030355A2 (en) | 2017-07-25 |
| BR112015030355A8 true BR112015030355A8 (en) | 2019-12-24 |
Family
ID=52008569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015030355A BR112015030355A8 (en) | 2013-06-07 | 2014-06-04 | use of a protein or an adenylyl cyclase type 6 (ac6) polypeptide incompetent with adenosine cyclic monophosphate (incompetent with camp) or a gene or nucleic acid encoding ac6mut, and, formulation |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11040091B2 (en) |
| EP (1) | EP3004343B1 (en) |
| JP (1) | JP6571069B2 (en) |
| KR (1) | KR20160032090A (en) |
| CN (1) | CN105452458A (en) |
| AU (1) | AU2014274902B2 (en) |
| BR (1) | BR112015030355A8 (en) |
| CA (1) | CA2914029A1 (en) |
| DK (1) | DK3004343T3 (en) |
| HK (1) | HK1222884A1 (en) |
| IL (1) | IL242885B (en) |
| RU (1) | RU2015155831A (en) |
| WO (1) | WO2014197624A1 (en) |
| ZA (1) | ZA201508942B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164920A1 (en) * | 2015-04-09 | 2016-10-13 | Cornell University | Gene therapy to prevent reactions to allergens |
| EP3530278A4 (en) * | 2016-10-24 | 2019-10-30 | Gwangju Institute of Science and Technology | Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases |
| WO2018090036A1 (en) * | 2016-11-14 | 2018-05-17 | Renova Therapeutics, Inc. | Method of protection for cardiac tissue |
| US11760987B2 (en) | 2017-09-07 | 2023-09-19 | The Regents Of The University Of California | Compositions and methods for the treatment or prevention of heart failure |
| JP7178118B2 (en) * | 2017-09-29 | 2022-11-25 | ベスファジェン・インコーポレイテッド | Pharmaceutical composition for preventing or treating arrhythmia |
| BR112020024935A2 (en) * | 2018-06-08 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | CARDIAC GENE THERAPY WITH AAV FOR CARDIOMYOPATHY |
| CN109010799B (en) * | 2018-07-09 | 2021-07-06 | 沣潮医药科技（上海）有限公司 | Application of RyR2 protein or RyR2 recombinant protein in preparation of anti-heart failure drugs |
| CN109191052B (en) * | 2018-10-22 | 2020-09-25 | 山东大学 | Multi-vehicle type vehicle path optimization method, server and system |
| EP4189098A1 (en) | 2020-07-27 | 2023-06-07 | Anjarium Biosciences AG | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1255822A2 (en) * | 1999-12-27 | 2002-11-13 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
-
2014
- 2014-06-04 WO PCT/US2014/040948 patent/WO2014197624A1/en active Application Filing
- 2014-06-04 CA CA2914029A patent/CA2914029A1/en not_active Abandoned
- 2014-06-04 RU RU2015155831A patent/RU2015155831A/en not_active Application Discontinuation
- 2014-06-04 EP EP14808138.3A patent/EP3004343B1/en active Active
- 2014-06-04 US US14/893,905 patent/US11040091B2/en active Active
- 2014-06-04 JP JP2016517971A patent/JP6571069B2/en active Active
- 2014-06-04 KR KR1020167000315A patent/KR20160032090A/en not_active Application Discontinuation
- 2014-06-04 CN CN201480044190.5A patent/CN105452458A/en active Pending
- 2014-06-04 BR BR112015030355A patent/BR112015030355A8/en not_active Application Discontinuation
- 2014-06-04 AU AU2014274902A patent/AU2014274902B2/en active Active
- 2014-06-04 DK DK14808138.3T patent/DK3004343T3/en active
-
2015
- 2015-12-02 IL IL242885A patent/IL242885B/en active IP Right Grant
- 2015-12-08 ZA ZA2015/08942A patent/ZA201508942B/en unknown
-
2016
- 2016-09-21 HK HK16111093.5A patent/HK1222884A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015155831A3 (en) | 2018-03-28 |
| IL242885B (en) | 2019-12-31 |
| EP3004343A4 (en) | 2017-01-04 |
| AU2014274902B2 (en) | 2020-06-04 |
| EP3004343B1 (en) | 2018-10-10 |
| DK3004343T3 (en) | 2019-02-04 |
| CA2914029A1 (en) | 2014-12-11 |
| JP2016521708A (en) | 2016-07-25 |
| KR20160032090A (en) | 2016-03-23 |
| US20160101164A1 (en) | 2016-04-14 |
| ZA201508942B (en) | 2019-05-29 |
| WO2014197624A1 (en) | 2014-12-11 |
| HK1222884A1 (en) | 2017-07-14 |
| CN105452458A (en) | 2016-03-30 |
| RU2015155831A (en) | 2017-07-14 |
| BR112015030355A2 (en) | 2017-07-25 |
| JP6571069B2 (en) | 2019-09-04 |
| AU2014274902A1 (en) | 2015-12-24 |
| US11040091B2 (en) | 2021-06-22 |
| EP3004343A1 (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015030355A8 (en) | use of a protein or an adenylyl cyclase type 6 (ac6) polypeptide incompetent with adenosine cyclic monophosphate (incompetent with camp) or a gene or nucleic acid encoding ac6mut, and, formulation | |
| BR112015027282A8 (en) | liquid formulation and kit comprising fenfluramine, and uses thereof in the treatment of dravet syndrome | |
| BR112018075960A2 (en) | nucleic acid molecules for reduction of papd5 or papd7 mrna for the treatment of hepatitis b infection | |
| BR112015001419A2 (en) | compound, pharmaceutical composition, and methods for inhibiting romk in a patient, causing diuresis, natriuresis, or both, and for treating one or more disorders. | |
| BR112015026006A2 (en) | methods for treating cancer with the use of tor kinase inhibitor combination therapy | |
| BR112014018331A8 (en) | BIOMARKERS AND COMBINED THERAPIES USING ONCOLYTIC VIRUSES AND IMMUNOMODULATION | |
| BR112015012295A2 (en) | methods for treating a patient, and kit for identifying a cancer patient | |
| BR112014018432A8 (en) | PROTEIN, IMMUNOGENIC COMPOSITION, METHOD FOR PRODUCING PROTEIN AND FOR TREATING OR PREVENTING DISEASE, NUCLEIC ACID MOLECULE, VECTOR, HOST CELL, USE OF A PROTEIN, AND, USE OF AN IMMUNOGENIC COMPOSITION | |
| BR112015027528A2 (en) | polypeptide, pharmaceutical combination, methods of treating a metabolic and obesity disorder, use of a polypeptide or pharmaceutical combination, nucleic acid molecule, expression vector, and host cell | |
| BR112015013700A2 (en) | composition, nucleotide sequence, synthetic antibody, and use of the composition | |
| BR112018002046A2 (en) | Lennox-Gastaut Syndrome Treatment Methods Using Fenfluramine | |
| BR112016029041A8 (en) | use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit | |
| BR112018008766A2 (en) | variants, compositions and methods and uses of the reduced factor viii cpg for the treatment of hemostasis disorders | |
| BR112016024352A2 (en) | "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual" | |
| BR112017001162A2 (en) | methods to treat paramyxovirus | |
| BR112012005225B8 (en) | USE OF AN ACTRIIB-FC FUSION PROTEIN FOR THE TREATMENT OF A DISORDER RELATED TO BONE OR ASSOCIATED WITH MUSCLE LOSS DUE TO FAULT MUSCLE GROWTH | |
| BR112014008529A2 (en) | humanized il-6 and il-6 receptor | |
| EP4324845A3 (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
| BR112015012197A8 (en) | cdk mtor inhibitor uses, and pharmaceutical combination comprising the same | |
| BR112015020209A2 (en) | use of linagliptin in antidiabetic therapy of cardiac and renal protection | |
| BR112016015660A2 (en) | neuregulin pharmaceutical formulation (nrg) and lyophilized neuregulin pharmaceutical formulation (nrg) | |
| BR112018069515A2 (en) | use of masitinib to treat a subpopulation of patients with amyotrophic lateral sclerosis | |
| BR112013032251A2 (en) | stable composition of the inactivated chikungunya virus strain vaccine with one or more mutations; method for inducing a protective immune response in human individuals against chikungunya virus infections; use of chikungunya virus isolates; combined vaccine composition | |
| BR112015022514A2 (en) | compositions comprising selenium and their use for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction | |
| MX2014010664A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |